查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1858255

反義和RNAi療法市場（按寡核苷酸類型、給藥途徑、治療領域和最終用戶分類）—2025-2032年全球預測

Antisense & RNAi Therapeutics Market by Oligonucleotide Type, Mode Of Administration, Therapeutic Areas, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，反義和 RNAi 療法市場將成長至 152.3 億美元，複合年成長率為 15.59%。

關鍵市場統計數據
基準年 2024 47.7億美元
預計年份：2025年 54.8億美元
預測年份 2032 152.3億美元
複合年成長率 (%) 15.59%

將分子創新與反義和RNAi療法的臨床前景結合，以重新定義治療模式、給藥方式和患者療效。

反義寡核苷酸和RNA干擾（RNAi）療法正從小眾科學研究走向主流治療方法，影響著多個治療領域和臨床策略。過去十年，化學、遞送平台和監管科學的進步，使得從分子概念到臨床概念驗證和核准產品的路徑更加清晰。因此，從小型專業生技公司到大型綜合製藥公司，相關人員將寡核苷酸平台視為解決傳統難治性標靶的核心資產。相應地，研發團隊目前正努力在早期創新與生產規模化、安全性評估和以病人為中心的給藥方案等實際問題之間取得平衡。

同時，臨床項目也不斷多元化。研究範圍已從罕見遺傳疾病擴展到更廣泛的治療領域，在這些領域中，基因表現調控提供了一種差異化的作用機制。這種拓展得益於一些新技術，這些技術能夠提高組織標靶性、減少脫靶效應並降低給藥頻率，增強了反義寡核苷酸和RNA干擾藥物的臨床和商業性合理性。此外，分析方法和臨床前模型的改進也提高了轉化研究的信心，並使從研究到臨床的轉化路徑更加快速、迭代。

重要的是，這種不斷變化的格局需要整合思維。科學創新必須與供應鏈韌性、監管協作以及以支付方觀點的證據產生相輔相成。隨著研發週期縮短和監管路徑日益清晰，專案團隊必須儘早協調跨職能協作，並以高度嚴謹的營運執行。本導言為深入探討重塑該領域的變革性轉變、影響全球供應鏈的政策和貿易動態，以及領導者在設計產品組合和商業化策略時應考慮的實際細分和區域差異奠定了基礎。

平台成熟、監管政策明朗化以及協作營運模式正在重塑反義和RNAi產品的開發和商業化路徑。

反義和RNAi療法領域正經歷著變革性的轉變，這主要得益於平台成熟度、監管政策的明朗化以及更廣泛的臨床應用目標的共同推動。平台成熟度的提升體現在兩個方面：化學設計和偶聯策略的進步提高了藥物的穩定性和療效；遞送技術的創新則拓展了藥物作用範圍，使其能夠覆蓋肝臟以外的組織。這些技術進步降低了標靶選擇的傳統障礙，使得藥物研發計畫能夠優先考慮患者的便利性和長期依從性。因此，藥物研發公司正在積極探索心血管疾病、代謝性疾病和神經退化性疾病等先前在技術和商業性都極具挑戰性的適應症。

監管路徑也在不斷調整，監管機構對寡核苷酸獨特的風險獲益特徵有了更深入的了解。這種理解使得圍繞非臨床資料包、生物標記策略和安全性監測的對話更加可預測，從而縮短了從早期臨床試驗到療效研究的週期。同時，臨床試驗設計也在不斷發展，變得更加靈活和以生物標記主導，從而支持更精準的臨床實驗群體選擇和更清晰的作用機制論證。因此，研發人員從研發初期就開始利用轉換終點和真實世界數據（RWE）框架，為支付者建構更具相關性的資料。

商業性和營運行為也與這些科學和監管變化保持同步。研發人員優先考慮生產擴充性和先進的分析技術，以降低CMC活動的風險，同時透過合作和聯盟將臨床能力與專業的合約開發和生產組織（CDMO）聯繫起來。這些合作模式使規模較小的申辦者能夠在維持對科學的策略控制的同時，利用所需的產業資源來推進後期開發並最終推向市場。這些變化共同拓展了臨床可行性的定義，並重塑了研發和商業化領域的策略格局。

評估2025年美國關稅對寡核苷酸療法原料採購、生產物流和全球供應的影響

2025年關稅政策環境將對寡核苷酸價值鏈產生重大影響，該價值鏈涉及原料採購、特殊試劑和關鍵耗材的跨境流動。關稅將增加進口核苷酸、修飾亞磷醯胺、脂質體配方用脂質以及某些酶的成本，這將給製造商帶來即時的成本壓力，並可能影響製程規模化和商業化生產位置決策。從長遠來看，持續存在的貿易壁壘可能會促使供應鏈區域化，並投資於國內或鄰近地區的生產能力，以降低進口波動帶來的風險。

在營運層面，進口成本上升通常會導致採購前置作業時間延長，促使買家整合訂單以擴大規模或重新認證多家供應商以實現冗餘。這種現象凸顯了供應商關係管理、品質監控和庫存管理政策的重要性。申辦方和契約製造製造商的策略性因應措施可能包括：簽訂多年合約、投資替代化學技術以減少對高關稅風險原料的依賴，或在可行的情況下加快垂直整合策略。此外，還需考慮工藝變更的監管時間表。關鍵原料的採購可能需要額外的製程驗證和監管諮詢，這可能會限制臨床供應策略的靈活性。

從策略角度來看，關稅驅動的改變既帶來挑戰也帶來機會。雖然成本上升會在短期內造成不利影響，但同時也會促使企業投資於國內製造業產能、本地人才培養和流程效率提升，進而增強長期供應鏈的韌性。此外，政策不確定性的增加通常會提升採購多元化和健全風險管理方案的價值。因此，那些積極建立關稅情境模型、將替代方案納入採購和生產計劃並根據需要與政策相關人員溝通的企業，將更有利於在貿易中斷的情況下保持發展勢頭。

細分市場洞察揭示了寡核苷酸類型、遞送方法、治療標靶和最終用戶如何影響研發重點和商業化選擇。

細分市場分析突顯了科學機會與商業性可行性的交會點，理解這些細分市場對於投資優先排序和商業模式設計至關重要。基於寡核苷酸類型的分類將市場分類為反義寡核苷酸和干擾性RNAi。在干擾性RNAi中，進一步區分了微干擾RNA和小干擾RNA，二者在效力、劑量預期和遞送方式方面各有不同。這些分子差異決定了化學結構、偶聯策略和毒性監測等方面的項目選擇，同時也影響組織靶向和生物標記策略的選擇。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 新興的脂質體奈米顆粒遞送系統可提高siRNA的穩定性和細胞攝取率。
  • 標靶定向寡核苷酸療法的配體結合平台開發
  • 透過將 CRISPR-Cas13 RNA 編輯技術與 RNAi 療法結合來實現精確的基因靜默
  • 利用人工智慧最佳化反義序列設計並進行脫靶預測
  • 擴大RNAi藥物皮下製劑的給藥範圍，以提高患者依從性和給藥頻率
  • 針對罕見神經肌肉疾病（存在高度未滿足的醫療需求）的反義療法的臨床進展
  • 腫瘤學中針對多種疾病路徑的多效價siRNA構建體的進展
  • 監管協調努力旨在加速新型RNAi療法的全球核准

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 反義和RNAi療法市場（以寡核苷酸類型分類）

  • 反義寡核苷酸
  • 干擾RNAi
    • 微干擾RNA
    • 小干擾RNA

9. 反義和RNAi療法市場依給藥途徑分類

  • 鞘內給藥
  • 靜脈注射
  • 口服
  • 皮下注射
  • 外用

10. 反義和RNAi療法市場按治療領域分類

  • 循環系統
  • 免疫學
  • 代謝性疾病
  • 神經系統疾病
  • 腫瘤學
  • 眼科
  • 罕見疾病

第11章 反義和RNAi療法市場（按最終用戶分類）

  • CRO（受託研究機構）
  • 製藥公司
  • 研究所

12. 各地區反義與RNAi療法市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 反義和RNAi療法市場（按類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國反義與RNAi療法市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Acuitas Therapeutics Inc.
    • Alloy Therapeutics, Inc.
    • Alnylam Pharmaceuticals, Inc.
    • Arbutus Biopharma Corporation
    • Arrowhead Pharmaceuticals, Inc.
    • AstraZeneca plc
    • Bayer AG
    • Benitec Biopharma Limited
    • City Therapeutics
    • Danaher Corporation
    • Eli Lilly and Company
    • Evox Therapeutics Ltd
    • GenScript Biotech Corporation
    • GSK PLC
    • Ionis Pharmaceuticals, Inc.
    • Merck KGaA
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Ribocure Pharmaceuticals AB
    • Sanofi SA
    • Shanghai Argo Biopharmaceutical Co., Ltd.
    • Silence Therapeutics plc
    • Stoke Therapeutics, Inc.
    • Suzhou Ribo Life Science Co., Ltd.
    • Wave Life Sciences Ltd
Product Code: MRR-8E22B61932A7

The Antisense & RNAi Therapeutics Market is projected to grow by USD 15.23 billion at a CAGR of 15.59% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.77 billion
Estimated Year [2025] USD 5.48 billion
Forecast Year [2032] USD 15.23 billion
CAGR (%) 15.59%

Bridging molecular innovation and clinical promise in antisense and RNAi therapeutics to redefine treatment paradigms, delivery, and patient outcomes

Antisense and RNA interference (RNAi) therapeutics are transitioning from a niche scientific pursuit into a mainstream modality influencing multiple therapeutic areas and clinical strategies. Over the past decade, advances in chemistry, delivery platforms, and regulatory science have brought a clearer line of sight from molecular concept to clinical proof of concept, and increasingly to approved products. As a result, stakeholders ranging from small specialized biotechs to large, integrated pharmaceutical companies view oligonucleotide platforms as core assets for addressing previously intractable targets. Consequently, development teams are now balancing early-stage innovation with the practicalities of manufacturing scale, safety characterization, and patient-centric administration.

At the same time, clinical programs are diversifying. Research now extends beyond rare genetic diseases into more prevalent therapeutic segments where modulation of gene expression offers differentiated mechanisms of action. This expansion has been enabled by technologies that improve tissue targeting, reduce off-target effects, and enable lower dosing frequencies, thereby strengthening the clinical and commercial rationale for antisense oligonucleotides and RNAi agents. Further, improvements in analytical methods and preclinical models have increased confidence in translational choices, enabling a faster, more iterative path from bench to clinic.

Importantly, the evolving landscape requires integrated thinking: scientific innovation must be matched by supply chain resilience, regulatory engagement, and payer-forward evidence generation. As development cycles compress and regulatory pathways become better-understood, program teams must orchestrate cross-functional alignment early and execute with heightened operational rigor. This introduction sets the stage for a deeper exploration of the transformative shifts reshaping the field, the policy and trade dynamics that affect global supply chains, and the practical segmentation and regional nuances leaders must account for when designing portfolios and commercialization strategies.

Platform maturation regulatory clarity and collaborative operational models that are reshaping antisense and RNAi product development and commercialization pathways

The antisense and RNAi therapeutic landscape is undergoing transformative shifts driven by convergence of platform maturation, regulatory clarity, and broader clinical ambition. Platform maturation has been twofold: chemistry and conjugate strategies have improved stability and potency, while delivery innovations have extended reach into tissues beyond the liver. These technical advances have reduced historical barriers to target selection and enabled programs that prioritize patient convenience and long-term adherence. As a result, drug developers are increasingly exploring indications in cardiovascular, metabolic, and neurodegenerative diseases that were previously considered technically or commercially infeasible.

Regulatory pathways are also adapting, with agencies demonstrating greater familiarity with oligonucleotide-specific risks and benefit profiles. This familiarity permits more predictable interactions around nonclinical packages, biomarker strategy, and safety monitoring, which, in turn, shortens the cycle from early human trials to pivotal studies. In parallel, clinical trial design is becoming more adaptive and biomarker-driven, supporting enriched patient selection and clearer demonstration of mechanism. Consequently, sponsors are leveraging translational endpoints and real-world evidence frameworks to build payer-relevant dossiers earlier in development.

Commercial and operational behaviors are aligning with these scientific and regulatory shifts. Developers are prioritizing manufacturing scalability and advanced analytics to de-risk CMC activities, while partnerships and alliances link clinical capabilities with specialized contract development and manufacturing organizations. These collaborative structures enable smaller sponsors to retain strategic control of their science while accessing the industrial capabilities necessary to move programs through late-stage development and into the market. Taken together, these shifts are expanding the definition of clinical viability and redefining strategic playbooks across research, development, and commercialization.

Evaluating how 2025 US tariff actions could reshape raw material sourcing, manufacturing logistics, and global supply of oligonucleotide therapeutics

The policy environment created by tariff measures in 2025 has important implications for the oligonucleotide value chain, where raw material sourcing, specialized reagents, and critical consumables traverse international borders. Tariffs that raise the cost of imported nucleotides, modified phosphoramidites, lipids used in lipid nanoparticle formulations, and select enzymes could create immediate cost pressure for manufacturers and impact decisions about where to site process scale-up and commercial production. Over time, sustained trade barriers can encourage greater regionalization of supply chains and foster investment in domestic or nearshore production capacity to mitigate exposure to import volatility.

Operationally, higher import costs will often translate into longer procurement lead times as buyers consolidate orders to achieve scale or requalify multiple suppliers for redundancy. In turn, this behavior places a premium on supplier relationship management, quality oversight, and inventory policies. For sponsors and contract manufacturers, the strategic response may include securing multi-year contracts, investing in alternate chemistries that reduce reliance on tariff-exposed inputs, or accelerating vertical integration strategies where feasible. Regulatory timelines for process changes must also be considered, as re-sourcing critical raw materials can require additional process validation and regulatory communications, potentially constraining the flexibility of clinical supply strategies.

Strategically, tariff-induced shifts can yield both challenge and opportunity. While cost increases present near-term headwinds, they can motivate investments in domestic manufacturing capacity, regional talent development, and improved process efficiencies that strengthen long-term supply resilience. Moreover, policy uncertainty typically increases the value of diversified sourcing and robust risk management programs. Consequently, organizations that proactively model tariff scenarios, incorporate contingency options into procurement and manufacturing plans, and engage with policy stakeholders where appropriate will be better positioned to maintain development momentum despite trade disruptions.

Segmentation insights demonstrating how oligonucleotide type, administration mode, therapeutic targets, and end users shape R&D focus and commercialization choices

Segmentation analysis provides clarity on where scientific opportunity and commercial viability intersect, and understanding these segments is critical for prioritizing investment and operational design. Based on Oligonucleotide Type, the landscape differentiates antisense oligonucleotides and interfering RNAi; within interfering RNAi, programs further distinguish between micro interfering RNAs and small interfering RNAs, each with distinct potency, dosing expectations, and delivery considerations. These molecular distinctions drive program-level choices in chemistry, conjugation strategies, and toxicity monitoring, and also inform the selection of tissue targets and biomarker strategies.

Based on Mode Of Administration, development paths and patient adoption profiles diverge significantly across intrathecal, intravenous, oral, subcutaneous, and topical routes. Administration mode influences formulation science, cold chain and logistics requirements, and the design of clinical operations; for example, intrathecal and intravenous routes often necessitate facility-based administration and more complex safety monitoring, while subcutaneous and oral options support decentralized models that can improve patient retention and real-world uptake. As a result, companies must weigh the trade-offs between clinical efficacy, patient convenience, and the downstream implications for reimbursement and market access.

Based on Therapeutic Areas, program portfolios reflect a breadth of indication choices, spanning cardiovascular, immunology, metabolic disorders, neurological disorders, oncology, ophthalmology, and rare diseases. Each therapeutic area carries unique regulatory expectations, clinical endpoint challenges, and competitive dynamics. For instance, neurology and rare disease programs may rely heavily on validated biomarkers and patient registries, whereas oncology and cardiovascular initiatives may require larger, event-driven trials and differentiated value propositions for payers. Strategic alignment between therapeutic focus and platform strengths is therefore a core determinant of program design and resource allocation.

Based on End User, the market's ecosystem includes contract research organizations, pharmaceutical companies, and research laboratories that collectively shape innovation cycles and commercialization pathways. Contract research organizations play an increasingly central role in providing specialized development and manufacturing capabilities that lower barriers for sponsors. Pharmaceutical companies contribute commercial scale, regulatory expertise, and payer engagement capabilities, while research laboratories drive early discovery and mechanistic understanding. The interplay among these end users determines how capabilities are assembled, how risks are shared, and how innovations ultimately reach patients.

Regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific shaping development hubs, manufacturing, regulations, and patient access

Regional dynamics exert outsized influence on development strategies, manufacturing footprints, and go-to-market planning, with distinct capability clusters emerging across geographies. In the Americas, dense biotech ecosystems and advanced clinical infrastructure support rapid proof-of-concept studies and growing manufacturing networks that prioritize scale and regulatory familiarity. These conditions make the region attractive for late-stage development and commercial launches, while access to venture and public capital continues to drive innovation in platform technologies and first-in-class programs.

In Europe, Middle East & Africa, a mix of academic excellence, regulatory harmonization within certain jurisdictions, and evolving industrial policy encourages partnerships and center-of-excellence models. Sponsors targeting these markets often coordinate multi-jurisdictional regulatory strategies and leverage regional manufacturing hubs to serve multiple neighboring markets efficiently. Policy incentives and public-private collaborations in parts of this region also encourage investment in capacity expansion and advanced analytics.

Across Asia-Pacific, capacity expansion, government-supported industrial initiatives, and a rapidly maturing clinical research environment are reshaping supply and demand dynamics. Increasing local manufacturing capabilities and talent pools create opportunities for nearshore sourcing and regional clinical acceleration. Consequently, many organizations are evaluating hybrid development models that combine western clinical development with Asia-Pacific manufacturing or clinical execution to optimize timelines, cost, and patient recruitment. Taken together, these regional patterns underscore the importance of aligning portfolio design with geographic strengths to optimize development velocity and commercial access.

Competitive and collaborative company strategies alliances and platform investments accelerating pipelines and scaling manufacturing for RNA-based therapies

Company behaviors in the oligonucleotide sector reflect a balance of competition and collaboration, with strategic alliances and platform investments driving acceleration of pipelines and scaling of manufacturing. Leaders in the space are investing in chemistry innovations, conjugate technologies, and delivery systems such as lipid-based carriers or receptor-targeting conjugates to expand tissue reach and improve safety margins. These investments are complemented by selective M&A and partnership activity that brings together discovery capabilities with late-stage development and commercialization resources.

Beyond scientific investments, companies are making deliberate choices about how to structure manufacturing operations. Some sponsors opt to partner with specialized contract development and manufacturing organizations to access scale quickly, while others pursue vertically integrated models to retain greater control over critical process steps and supply security. In either case, investments in analytical capabilities, process automation, and regulatory-ready quality systems are common priorities, as they materially reduce the time and risk associated with scale-up and commercial release.

Collaboration extends to payer and provider engagement as well. Forward-looking companies are modeling long-term value propositions that incorporate dosing convenience, durability of effect, and real-world outcomes to build evidence packages that resonate with health systems. Partnerships that align clinical development with payer expectations and delivery systems enhance the probability of favorable access conditions and smoother rollout strategies. Overall, corporate strategies emphasize platform differentiation, manufacturing resilience, and cross-sector engagement to convert scientific potential into durable clinical and commercial success.

Practical strategic actions for industry leaders to optimize delivery, de-risk development, and accelerate clinical adoption of antisense and RNAi therapies

Industry leaders can pursue a set of prioritized, actionable recommendations to enhance resilience and accelerate value realization across antisense and RNAi programs. First, integrate delivery and CMC considerations early in the discovery process so that platform choices align with manufacturability, regulatory expectations, and patient administration preferences. Early co-optimization of chemistry and formulation reduces late-stage rework and shortens the path to reproducible, scalable manufacturing. Second, diversify supplier networks and qualify alternate raw material sources to mitigate supply chain risk; scenario planning for tariff-impacted inputs and critical reagents should be embedded into procurement and program risk registers.

Third, pursue collaborative models that leverage specialized CDMOs and research partners to access capacity and technical expertise without overextending capital deployment. Strategic alliances that include shared development milestones and de-risking mechanisms can accelerate timelines while preserving upside for original innovators. Fourth, design clinical programs with payer-relevant endpoints and real-world evidence components that anticipate market access questions earlier in development; this alignment increases the probability of reimbursement and supports broader adoption post-launch. Fifth, invest in regulatory strategy and proactive engagement with authorities to clarify expectations around nonclinical safety, biomarker qualification, and comparability as manufacturing scales. Proactive regulatory planning reduces uncertainty and supports more efficient submission packages.

Finally, prioritize workforce capability building and cross-functional governance to manage complex development portfolios effectively. Establish multidisciplinary teams that align discovery, translational science, CMC, clinical operations, and commercial planning to ensure decisions are made with a holistic view of program risks and opportunities. Collectively, these actions create a practical roadmap for leaders seeking to translate molecular promise into patient impact while controlling development complexity and commercial risk.

Clear research methodology outlining primary and secondary approaches expert interviews and data triangulation applied to antisense and RNAi therapeutic analysis

This analysis is grounded in a mixed-methods research approach that combines primary qualitative insights and rigorous secondary synthesis to create an evidence-based narrative. Primary inputs include structured interviews with subject-matter experts across discovery, CMC, clinical operations, and commercial functions, which offer context on operational challenges, technology adoption curves, and strategic priorities. These conversations were supplemented by targeted consultations with manufacturing leaders and regulatory affairs specialists to ensure practical grounding in scale-up realities and compliance expectations.

Secondary research entailed systematic review of peer-reviewed literature, regulatory guidance documents, public company disclosures, and technical white papers that illuminate technology advances, safety considerations, and clinical trends. Data from diverse sources were triangulated to identify consistent signals, reconcile differences, and highlight areas of emerging consensus or uncertainty. Throughout the process, findings were validated against expert perspectives to refine interpretation, ensure factual accuracy, and surface actionable implications for decision-makers.

Concise synthesis highlighting strategic imperatives key challenges and practical pathways for stakeholders advancing antisense and RNAi therapeutic development

The synthesis presented here underscores a sector at an inflection point: platform and delivery innovations are broadening the clinical applicability of antisense and RNAi modalities even as commercial and operational complexities increase. Key imperatives include aligning platform choices with manufacturability, building resilient supply chains that account for trade and tariff uncertainty, and designing clinical programs that address payer and provider evidence needs. Stakeholders who combine scientific ambition with disciplined operational execution and strategic partnerships will be best positioned to convert technical advances into durable patient and commercial outcomes.

Persistent challenges remain, including tissue-specific delivery beyond canonical targets, long-term safety characterization, and the logistical demands of scalable manufacturing. Nonetheless, by prioritizing early alignment across discovery, CMC, and clinical functions and by proactively managing external risks such as trade policy shifts, organizations can navigate the complexity and capture the value this therapeutic class offers. The conclusion is pragmatic: success will favor those who pair innovation with operational foresight and market-oriented evidence generation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emerging lipid nanoparticle delivery systems enhancing siRNA stability and cellular uptake
  • 5.2. Development of ligand conjugation platforms for targeted antisense oligonucleotide therapies
  • 5.3. CRISPR-Cas13 mediated RNA editing integration with RNAi therapeutics for precise gene silencing
  • 5.4. Utilization of artificial intelligence for optimized antisense sequence design and off-target prediction
  • 5.5. Expansion of subcutaneous formulations for RNAi drugs to improve patient compliance and dosing frequency
  • 5.6. Clinical progress in antisense therapies for rare neuromuscular disorders with high unmet medical need
  • 5.7. Advancements in multivalent siRNA constructs targeting multiple disease pathways in oncology
  • 5.8. Regulatory harmonization efforts accelerating global approval of novel RNAi-based therapeutics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antisense & RNAi Therapeutics Market, by Oligonucleotide Type

  • 8.1. Antisense Oligonucleotides
  • 8.2. Interfering RNAi
    • 8.2.1. Micro Interfering RNAs
    • 8.2.2. Small Interfering RNAs

9. Antisense & RNAi Therapeutics Market, by Mode Of Administration

  • 9.1. Intrathecal
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Subcutaneous
  • 9.5. Topical

10. Antisense & RNAi Therapeutics Market, by Therapeutic Areas

  • 10.1. Cardiovascular
  • 10.2. Immunology
  • 10.3. Metabolic Disorders
  • 10.4. Neurological Disorders
  • 10.5. Oncology
  • 10.6. Ophthalmology
  • 10.7. Rare Diseases

11. Antisense & RNAi Therapeutics Market, by End User

  • 11.1. Contract Research Organizations
  • 11.2. Pharmaceutical Companies
  • 11.3. Research Laboratories

12. Antisense & RNAi Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Antisense & RNAi Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Antisense & RNAi Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Acuitas Therapeutics Inc.
    • 15.3.2. Alloy Therapeutics, Inc.
    • 15.3.3. Alnylam Pharmaceuticals, Inc.
    • 15.3.4. Arbutus Biopharma Corporation
    • 15.3.5. Arrowhead Pharmaceuticals, Inc.
    • 15.3.6. AstraZeneca plc
    • 15.3.7. Bayer AG
    • 15.3.8. Benitec Biopharma Limited
    • 15.3.9. City Therapeutics
    • 15.3.10. Danaher Corporation
    • 15.3.11. Eli Lilly and Company
    • 15.3.12. Evox Therapeutics Ltd
    • 15.3.13. GenScript Biotech Corporation
    • 15.3.14. GSK PLC
    • 15.3.15. Ionis Pharmaceuticals, Inc.
    • 15.3.16. Merck KGaA
    • 15.3.17. Novo Nordisk A/S
    • 15.3.18. Pfizer Inc.
    • 15.3.19. Ribocure Pharmaceuticals AB
    • 15.3.20. Sanofi S.A.
    • 15.3.21. Shanghai Argo Biopharmaceutical Co., Ltd.
    • 15.3.22. Silence Therapeutics plc
    • 15.3.23. Stoke Therapeutics, Inc.
    • 15.3.24. Suzhou Ribo Life Science Co., Ltd.
    • 15.3.25. Wave Life Sciences Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANTISENSE & RNAI THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANTISENSE & RNAI THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTISENSE & RNAI THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MICRO INTERFERING RNAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MICRO INTERFERING RNAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MICRO INTERFERING RNAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MICRO INTERFERING RNAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MICRO INTERFERING RNAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MICRO INTERFERING RNAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRATHECAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRATHECAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRATHECAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
  • TABLE 160. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
  • TABLE 196. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 200. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
  • TABLE 208. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
  • TABLE 209. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 212. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
  • TABLE 213. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
  • TABLE 234. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
  • TABLE 235. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 236. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 237. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 238. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
  • TABLE 239. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
  • TABLE 246. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
  • TABLE 247. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 250. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
  • TABLE 251. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
  • TABLE 270. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
  • TABLE 271. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 274. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
  • TABLE 275. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
  • TABLE 282. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
  • TABLE 283. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 286. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2032 (USD MILLION)
  • TABLE 287. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2024 (USD MILLION)
  • TABLE 294. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2025-2032 (USD MILLION)
  • TABLE 295. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 296. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 20